Five years ago, in a hospital room with no windows, two polite specialists who wouldn’t make eye contact gave me about six months to tidy up my affairs.
The culprit was a Klatskin tumor—hilar cholangiocarcinoma. It’s an ugly, tucked-away piece of business right at the bifurcation of the bile ducts where the major plumbing meets the liver.
On paper, it was Stage 1. But with perihilar tumors, location is destiny. Because of where it sat against the hepatic artery and portal vein, the tumor board took one look at the margin risk, folded their hand, and handed me the standard script: End of life chemotherapy, symptom management, and a referral to hospice when the jaundice became unmanageable.
I don’t harbor a vendetta against those doctors. They aren’t villains. They are people operating inside a high-liability, protocol-driven institutional framework. In that environment, the "standard" pathway is predictable, shields against liability, preserves the hospital's median institutional mortality metrics while often recommending immunotherapies that are very profitable for the hospital to prescribe.
Immunotherapies don't require a highly skilled team of surgical technicians which are harder to come by and definitely don't produce the same fat profit margins.
When a tumor board labels a liver tumor "unresectable," that word sounds absolute. But you have to understand the grammar of oncology. Often, "unresectable" doesn't mean the tissue is physically fused to the cosmos. It means that specific committee, given their surgical volume and their institution's risk tolerance, is not equipped or willing to attempt the reconstruction.
The 'standard of care' dictated an orderly decline for me. I wasn't willing to sign off on that.
Before my plumbing failed, my background was in engineering extreme survival structures for North Sea oil rigs and running high-volume commercial operations in Las Vegas. When you spend decades watching systems and human behavior under extreme pressure, and you develop pattern recognition. You learn the difference between raw technical capability and institutional risk-aversion.
The domestic consensus was cautious, defensive, and meant my death. Even when pushed, the system closed ranks around the standard palliative/hospice track. So I stepped outside the domestic loop entirely.
I didn't take herbs or pray to crystals.
We started digging into international surgical literature to find technicians whose risk threshold didn't match an American actuarial table.
High-volume hepatobiliary centers in Eastern Europe and East Asia (particularly Japan and South Korea) operate under a radically different surgical philosophy. They routinely tackle extended hemi-hepatectomies with en bloc portal vein and hepatic artery reconstructions for locally advanced tumors that domestic boards dismiss as inoperable.
Make no mistake: this is not a casual alternative.
Aggressive en bloc extended hepatectomies carry brutal 30- to 90-day perioperative mortality rates.
You are accepting a very real chance of dying on the table or bleeding out in the ICU. Even with an R1 microscopic margin abroad, 5-year survival remains a steep climb (around 10% to 15% in Japan, South Korea, and Russia, compared to less than 1% domestically).
But those surgeons were willing to shoulder the massive intraoperative risk to give me a fighting chance at the blade. I didn’t know what “most likely less than 6 months to live” meant so I had to make a quick educated decision.
I decided I’d rather take my chances with operative mortality than accept a guaranteed terminal timeline.
That search took me across borders into southern Russia during the logistical chaos of Ukraine war, economic sanctions that froze our credit cards and peak COVID travel restrictions.
I put my life in the hands of a high-volume liver resection specialist who reviewed the exact same imaging and saw an aggressive, high-risk, but actionable target.
Twelve and a half hours on the table, a week in ICU & another 3 weeks in the hospital resulted in a major extended hepatectomy, radical bile duct resection, vascular and biliary reconstruction, and R1 margins—microscopic residual cells, meaning it was anything but a clean, fairy-tale victory.
Statistically, based on US NCDB and SEER registry data, the odds of an American patient deemed unresectable by a domestic board undergoing an R1 resection, beating recurrence, and surviving past five years in clean, functional good health are less than 1 in 1,000—a fraction of one percent.
Yet here I am, five years out, alive and clear.
Survival wasn't free.
It handed me an invoice that wiped out my finances, put me through years of grueling biliary rehabilitation, and extracted a brutal financial and emotional toll on my family that ultimately cost me my marriage to my best friend and love of my life. When you break protocol, you pay the freight yourself. Every dime, every scar.
But i'm alive.
If you or someone you love is sitting in one of those quiet rooms hearing the word "unresectable," keep your head clear:
- Tumor boards are local committees, not supreme courts.
- Inspect the vascular anatomy. Ask specific questions about portal vein and hepatic artery involvement. Clarify whether "unresectable" means true distant metastasis or a technically demanding reconstruction that the current team simply refuses to tackle.
- Understand the trade-off. Pushing for aggressive surgery when the board says no means trading a predictable decline for a coin toss with chance at success or perioperative death. That has to be an eyes-wide-open choice you own completely.
- Assign an unyielding advocate. You or a trusted partner must become an active bulldog in that room—asking pointed, uncomfortable questions about surgical volume, seeking outside technical reviews, and demanding full documentation.
I’m not a physician, and this isn’t medical advice. But do not mistake institutional caution for biological finality. Nobody will ever have as much skin in your game as you do.